Equity Research is published in the framework of the Tel
Aviv Stock Exchange (TASE) Analysis Program
TEL AVIV, Israel, July 5, 2018 /PRNewswire/ -- The TASE analysis
project was launched in 2016 in order to raise investors' awareness
to TASE listed technology and life-science companies and the
markets in which these companies operate, thus creating appropriate
pricing and increasing the exposure of investors from Israel and abroad. Its goal is to encourage
investments in these companies by improving understanding of these
industries and companies in the market.
In order to maintain professional, independent and unbiased
analysis, the companies signed an agreement with the TASE to
receive the analysis services for an obligatory period of two
years. The companies cannot withdraw from the project during this
period. The analysis is funded by the companies surveyed with
funding from the Chief Scientist and the TASE.
Summary of Highlights
- Kadimastem addresses the global ALS therapy market, which
stood at $53M in 2016 and is expected
to grow to between $468M and
$840M million by 2021, as new
therapies enter the market.
-
- According to the company, ALS also has a heavy economic burden
with estimated healthcare expenditure at $6B p.a. in the US alone.
- The company expects to complete phase I/IIa clinical trials by
August 2020. If it is able to
demonstrate the efficacy and safety of AstroRx in treating ALS
patients, it can further evaluate its AstroRx therapy for treating
other neurological disorders.
- Research suggests that astrocytes can play a positive role in
Alzheimer's disease, Parkinson's disease, multiple sclerosis and
epilepsy – diseases with no cure and pressing unmet needs.
- The market for insulin is expected to grow at a CAGR of 8.3%
and reach $43.6 billion by 2021.
Although the market is highly competitive, we assume there is room
for innovative companies, to enter and grow.
-
- The company is developing its diabetes program in collaboration
with French based medical device manufacturer Defymed.
- The companies' plan to conduct a joint proof of concept
pre-clinical test to combine the former's stem cell derived -
islet-of-Langerhans-like cell clusters (insulin secreting beta
cells) with the latter's medical device (MailPan) and evaluate the
efficacy of the combination in treating diabetes.
- We estimate the company's equity value at NIS 52.11M ($14.64M) corresponding to a target price ranging
between NIS 0.77 and NIS 0.93; a mean of NIS
0.85
-
- 2019 will be a crucial year for Kadimastem with the forecasted
release of one early-stage clinical trial results and a POC trial,
both which have the potential to impact the company's strategic
position within the stem cells domain.
- We see both short and long term investment potential in
Kadimastem stock
About the company - Kadimastem Ltd. (hereinafter
"Kadimastem" or "the company") is a clinical stage
biopharmaceutical company that specializes in developing different
types of human body cells (known as differentiated cells) – such as
neural cells (e.g. oligodendrocytes and astrocytes) and insulin
secreting beta cells, derived from human embryonic stem cells. The
company has its technological platform and two current stem cell
based therapies in research phase – AstroRx (consists of
astrocytes, a type of brain cell) and Encapsulin (insulin secreting
beta cells) for treating amyotrophic lateral sclerosis (ALS) and
diabetes respectively.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in
collaboration with clients to leverage visionary innovation that
addresses the global challenges and related growth opportunities
that will make or break today's market participants. For more than
50 years, we have been developing growth strategies for the global
1000, emerging businesses, the public sector and the investment
community. Contact us: Start the discussion.
Contact:
Kristi Cekani
Corporate Communications - Frost & Sullivan, Europe
P: +39.02.4851.6133
E: kristi.cekani@frost.com
http://www.frost.com
View original
content:http://www.prnewswire.com/news-releases/frost--sullivan-publishes-initial-coverage-report-on-kadimastem-ltd-kadimastem-offers-treatment-of-diabetes-and-neurological-diseases-such-as-als-by-cellular-therapy-company-is-pursuing-clinical-trial-als-and-pre-clinical-p-300676544.html
SOURCE Frost & Sullivan